CombiMatrix Molecular Diagnostics has completed the clinical validation of HemeScan MDS, an array comparative genomic hybridization-based test for myelodysplastic syndromes, according to its parent company CombiMatrix.
 
HemeScan MDS is designed to detect clonal prognostic markers in bone marrow aspirates from patients with refractory anemia. The test combines diagnosis of pre-leukemia with individualized risk stratification and treatment planning.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.